Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

Overview

• Pomerantz, which filed the case Thursday in the Central District of California under 26-cv-03083, seeks to represent buyers of Atara shares from May 20, 2024 to January 9, 2026.
• Rosen, Bronstein Gewirtz & Grossman, and Faruqi & Faruqi urged investors to seek lead plaintiff status by May 22, 2026, after announcing the same class period.
• The complaints say undisclosed problems at a third-party plant and basic flaws in the single-arm ALLELE study made FDA approval of the tabelecleucel application unlikely.
• Atara disclosed an FDA rejection tied to manufacturing on January 16, 2025, a clinical hold five days later, and a second rejection on January 12, 2026 after the agency said the ALLELE data could not prove benefit.
• Shares fell about 41% after the first rejection and 57% after the second, deepening investor losses and adding strain to a company that depends on partner Pierre Fabre for milestone funding.